Hepatorenal Syndrome: Outcome of Response to Therapy and Predictors of Survival
Open Access
- 23 April 2015
- journal article
- research article
- Published by Hindawi Limited in Gastroenterology Research and Practice
- Vol. 2015, 1-8
Abstract
Aim. Treatment of hepatorenal syndrome (HRS) in patients with liver cirrhosis is still challenging and characterized by a very high mortality. This study aimed to delineate treatment patterns and clinical outcomes of patients with HRS intravenously treated with terlipressin.Methods. In this retrospective single-center cohort study, 119 patients (median [IQR]; 56.50 [50.75–63.00] years of age) with HRS were included. All patients were treated with terlipressin and human albumin intravenously. Those with response to treatment () were compared to the patient cohort without improvement (). Patient characteristics and clinical parameters (Child stage, ascites, hepatic encephalopathy, HRS type I/II, and initial MELD score) were retrieved. Univariate analysis of factors influencing the success of terlipressin therapy and Cox regression analysis of factors influencing survival was carried out.Results. One-month survival was significantly longer in the group of responders (). Cox regression analysis identified age [Hazard ratio, 95% confidence interval (CI); 1.05, 1.01–1.09, resp.], alcohol abuse [HR 3.05, 95% CI 1.11–8.38], duration of treatment [HR 0.92, 95% CI 0.88–0.96], and MELD score [HR 1.08, 95% CI 1.02–1.14] to be independent predictors of survival.Conclusions. Survival of HRS patients after treatment depends on age, etiology of liver disease, and the duration of treatment.
Keywords
This publication has 49 references indexed in Scilit:
- Long‐term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosisJournal of Gastroenterology and Hepatology, 2013
- Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trialHepatology, 2012
- Pentoxifylline Does Not Decrease Short-term Mortality but Does Reduce Complications in Patients With Advanced CirrhosisGastroenterology, 2010
- Terlipressin and Albumin vs Albumin in Patients With Cirrhosis and Hepatorenal Syndrome: A Randomized StudyGastroenterology, 2008
- A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal SyndromeGastroenterology, 2008
- Circulatory function and hepatorenal syndrome in cirrhosis†Hepatology, 2005
- Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacinJournal of Hepatology, 2004
- Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangementHepatology, 2003
- A Model to Predict Survival in Patients With End–Stage Liver DiseaseHepatology, 2001
- LONG-TERM SURVIVAL AND RENAL FUNCTION FOLLOWING LIVER TRANSPLANTATION IN PATIENTS WITH AND WITHOUT HEPATORENAL SYNDROMETransplantation, 1991